Bioresorbable scaffolds: should we stay simple or go complex?
作者信息
Ortega-Paz Luis, Brugaletta Salvatore, Garcia-Garcia Hector M, Sabaté Manel
机构信息
Institut Clinic Cardiovascular, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), IDIBAPS, University of Barcelona, Barcelona, Spain.
Department of Internal Medicine, Division of Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.
出版信息
Cardiovasc Diagn Ther. 2017 Jun;7(3):E7-E12. doi: 10.21037/cdt.2017.01.07.
Abstract
摘要
相似文献
1
Bioresorbable scaffolds: should we stay simple or go complex?生物可吸收支架：我们应该保持简单还是走向复杂？
Cardiovasc Diagn Ther. 2017 Jun;7(3):E7-E12. doi: 10.21037/cdt.2017.01.07.
2
[Complex coronary intervention with overlapping of bioresorbable scaffolds. Case report and new insights review in the use of bioresorbable vascular scaffolds guided by optical coherence tomography].[生物可吸收支架重叠的复杂冠状动脉介入治疗。光学相干断层扫描引导下生物可吸收血管支架应用的病例报告及新见解综述]
Arch Cardiol Mex. 2016 Apr-Jun;86(2):170-4. doi: 10.1016/j.acmx.2016.01.003. Epub 2016 Feb 21.
3
Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.依维莫司洗脱生物可吸收血管支架与依维莫司洗脱金属支架的比较：随机对照试验的荟萃分析。
Lancet. 2016 Feb 6;387(10018):537-544. doi: 10.1016/S0140-6736(15)00979-4. Epub 2015 Nov 17.
4
Bioresorbable scaffolds for coronary artery disease: current status and future prospective.用于冠状动脉疾病的生物可吸收支架：现状与未来展望。
Chin Med J (Engl). 2014;127(6):1141-8.
5
Bioresorbable vascular scaffolds: Biodegradation, drug delivery and vascular remodeling.生物可吸收血管支架：生物降解、药物递送与血管重塑。
Pharmacol Res. 2016 May;107:163-171. doi: 10.1016/j.phrs.2016.03.020. Epub 2016 Mar 18.
6
Personal Experience with Bioresorbable Scaffolds in Bifurcations.分叉病变中生物可吸收支架的个人经验
Interv Cardiol. 2013 Aug;8(2):93-95. doi: 10.15420/icr.2013.8.2.93.
7
Fabrication and Characterization of Bioresorbable Drug-coated Porous Scaffolds for Vascular Tissue Engineering.用于血管组织工程的生物可吸收药物涂层多孔支架的制备与表征
Materials (Basel). 2019 May 2;12(9):1438. doi: 10.3390/ma12091438.
8
Absorb Bioresorbable Vascular Scaffold in Complex Coronary Bifurcation Interventions: Insights From an In Vivo Multimodality Imaging Study.在复杂冠状动脉分叉病变介入治疗中应用可吸收生物可降解血管支架：一项体内多模态影像学研究的启示。
Circ Cardiovasc Interv. 2016 Aug;9(8). doi: 10.1161/CIRCINTERVENTIONS.116.003849.
9
Complex bifurcation lesions: Randomized comparison of a fully bioresorbable modified t stenting strategy versus bifurcation reconstruction with a dedicated self-expanding stent in combination with bioresorbable scaffolds, an OCT study: Rationale and design of the COBRA II trial.复杂分叉病变：完全可生物吸收的改良T型支架置入策略与使用专用自膨胀支架联合生物可吸收支架进行分叉重建的随机对照研究：一项光学相干断层扫描（OCT）研究——COBRA II试验的原理与设计
Catheter Cardiovasc Interv. 2016 Nov 15;88(6):843-853. doi: 10.1002/ccd.26571. Epub 2016 May 17.
10
From drug eluting stents to bioresorbable scaffolds; to new horizons in PCI.从药物洗脱支架到生物可吸收支架；再到经皮冠状动脉介入治疗的新视野。
Expert Rev Med Devices. 2016;13(3):271-86. doi: 10.1586/17434440.2016.1143356. Epub 2016 Feb 12.
本文引用的文献
1
Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions: The BONITO Registry (Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions).生物可吸收支架与药物洗脱支架治疗慢性完全闭塞病变的手术及长期预后：BONITO注册研究（生物可吸收支架与药物洗脱支架治疗慢性完全闭塞病变）
Circ Cardiovasc Interv. 2016 Oct;9(10). doi: 10.1161/CIRCINTERVENTIONS.116.004284.
2
Overview of the 2016 U.S. Food and Drug Administration Circulatory System Devices Advisory Panel Meeting on the Absorb Bioresorbable Vascular Scaffold System.2016 年美国食品和药物管理局循环系统设备顾问小组会议概述：Absorb 生物可吸收血管支架系统。
JACC Cardiovasc Interv. 2016 Sep 12;9(17):1757-64. doi: 10.1016/j.jcin.2016.06.027.
3
Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry.在常规临床实践中接受依维莫司洗脱生物可吸收支架植入的患者中，重叠对1年临床结局的影响：来自欧洲多中心GHOST-EU注册研究的见解
Catheter Cardiovasc Interv. 2017 Apr;89(5):812-818. doi: 10.1002/ccd.26674. Epub 2016 Aug 12.
4
Two-year clinical outcomes of Absorb bioresorbable vascular scaffold implantation in complex coronary artery disease patients stratified by SYNTAX score and ABSORB II study enrolment criteria.SYNTAX 评分和 ABSORB II 研究入选标准分层的复杂冠状动脉疾病患者中 Absorb 生物可吸收血管支架植入术的 2 年临床结果。
EuroIntervention. 2016 Aug 5;12(5):e557-65. doi: 10.4244/EIJV12I5A95.
5
Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.依维莫司洗脱生物可吸收血管支架治疗患者的中期至长期临床结局：BVS Expand 注册研究。
JACC Cardiovasc Interv. 2016 Aug 22;9(16):1652-63. doi: 10.1016/j.jcin.2016.04.035. Epub 2016 Jul 27.
6
Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry.生物可吸收血管支架用于冠状动脉分叉病变：来自GHOST EU注册研究的一项子研究。
Catheter Cardiovasc Interv. 2017 Jan;89(1):47-56. doi: 10.1002/ccd.26634. Epub 2016 Jul 14.
7
The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.在 ABSORB II 试验中，生物可吸收依维莫司洗脱支架和金属依维莫司洗脱支架的术后对称性、扩张和偏心对临床结果的影响。
JACC Cardiovasc Interv. 2016 Jun 27;9(12):1231-1242. doi: 10.1016/j.jcin.2016.03.027. Epub 2016 Jun 1.
8
A novel approach to treat in-stent restenosis: 6- and 12-month results using the everolimus-eluting bioresorbable vascular scaffold.一种治疗支架内再狭窄的新方法：使用依维莫司洗脱的生物可吸收血管支架的 6 个月和 12 个月结果。
EuroIntervention. 2016 Apr 20;11(13):1479-86. doi: 10.4244/EIJV11I13A287.
9
Bioresorbable vascular scaffolds in clinical practice: state-of-the-art.生物可吸收血管支架在临床实践中的应用：最新进展
Panminerva Med. 2016 Jun;58(2):130-42. Epub 2016 Apr 16.
10
Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors.生物可吸收冠状动脉支架血栓形成：多中心临床特征、机制和预测因素的综合分析。
J Am Coll Cardiol. 2016 Mar 1;67(8):921-931. doi: 10.1016/j.jacc.2015.12.019.
Zotero 插件